User profiles for SVEN MAHNER

Sven Mahner

University of Munich
Verified email at med.uni-muenchen.de
Cited by 19641

[HTML][HTML] Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer

…, BJ Monk, J Herrstedt, AM Oza, S Mahner… - … England Journal of …, 2016 - Mass Medical Soc
Background Niraparib is an oral poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP)
1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought …

[HTML][HTML] A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms

…, W Meier, D Cibula, A Mustea, S Mahner… - … England Journal of …, 2019 - Mass Medical Soc
Background Systematic pelvic and paraaortic lymphadenectomy has been widely used in the
surgical treatment of patients with advanced ovarian cancer, although supporting evidence …

Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO …

…, G Scambia, D Cibula, S Mahner… - International Journal of …, 2011 - ijgc.bmj.com
Purpose: The DESKTOP I trial proposed a score for the prediction of complete cytoreduction
in recurrent ovarian cancer. Resectability was assumed if 3 factors were present: (1) …

Adjuvant therapy in lymph node–positive vulvar cancer: the AGO-CaRE-1 study

S Mahner, J Jueckstock, F Hilpert… - Journal of the …, 2015 - academic.oup.com
Background: Women with node-positive vulvar cancer have a high risk for disease recurrence.
Indication criteria for adjuvant radiotherapy are controversial. This study was designed to …

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

C Marth, F Landoni, S Mahner… - Annals of …, 2017 - annalsofoncology.org
Cervical cancer is the second most commonly diagnosed cancer and the third leading cause
of cancer death among females in less developed countries. There were an estimated 527 …

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

…, J Špaček, P Vuylsteke, H Hirte, S Mahner… - The lancet …, 2015 - thelancet.com
Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour
activity in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with or …

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label …

…, N Spirtos, N Concin, S Mahner… - The Lancet …, 2021 - thelancet.com
Background Few effective second-line treatments exist for women with recurrent or metastatic
cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of tisotumab …

[PDF][PDF] Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F] …

…, M Untch, R Tiling, S Sassen, S Mahner… - J Clin Oncol, 2009 - Citeseer
… Jörg Schwarz-Dose, Michael Untch, Reinhold Tiling, Stefanie Sassen, Sven Mahner,
Steffen Kahlert, Nadia Harbeck, Annette Lebeau, Winfried Brenner, Markus Schwaiger, Fritz …

[HTML][HTML] Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group

…, N De Gregorio, A Reuss, S Mahner… - European journal of …, 2013 - Elsevier
BACKGROUND: Borderline ovarian tumours (BOTs) are recognised as a unique entity of
ovarian tumours that do not exert infiltrative destructive growth or stromal invasion. Prognosis of …

European Society of Gynaecological Oncology guidelines for the management of patients with vulvar cancer

…, M Brännström, F Landoni, S Mahner… - International Journal of …, 2017 - ijgc.bmj.com
Objective The aim of this study was to develop clinically relevant and evidence-based
guidelines as part of European Society of Gynaecological Oncology’s mission to improve the …